Long-term surveillance of small renal masses is safe

In a recent study published in Journal of Urology and involving over 100 mostly older patients, almost all of the patients with small kidney tumours never developed advanced cancer or died of the disease during more than 4 years of follow-up in active surveillance. More than half of the patients remained alive without metastatic disease […]

read more

Stereotactic radiosurgery is successful for RCC brain metastases

A recent study of 362 patients with brain metastases from renal cell carcinoma (RCC) were treated with stereotactic radiosurgery to remove the metastases. The researchers concluded that stereotactic radiosurgery is highly effective in patients with brain metastases from RCC, and concomitant use of tyrosine kinase inhibitors (TKIs), such as sunitinib and pazopanib, does not suggest […]

read more

Low PD-L1 associated with long term response to sunitinib

Researchers from France have conducted a study to show that metastatic clear cell renal cell carcinoma (RCC) patients who have low expression of PD-L1 also have a long term response to sunitinib. However, low PD-L1 levels suggest a potentially lower impact of immunotherapy in these patients. Read more in Clinical Genitourinary Cancer here

read more

SMC approves nivolumab plus ipilimumab combination for advanced RCC

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of nivolumab plus ipilimumab for intermediate-/poor-risk advanced renal cell carcinoma (RCC) by NHS Scotland. The nivolumab (Opdivo) plus ipilimumab (Yervoy) combination was accepted following consideration through the SMC’s Patient and […]

read more

ASCO 2019: Effectiveness of pazopanib after kidney cancer metastasectomy

In this phase III study, presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago this week, the use of treatment with pazopanib after surgery to remove renal cell carcinoma (RCC) metastases (metastasectomy) was investigated. One hundred and twenty-nine patients with no evidence of disease after surgery to remove RCC metastases […]

read more

ASCO 2019: Human endogenous retrovirus and efficacy of checkpoint inhibitors in kidney cancer

This paper was presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago earlier this week. Human endogenous retrovirus (hERV) is an ancient virus that is found in the human genome; about 8% of the human genome is hERV. HERVs have been inherited by successive generations and it is possible that […]

read more

Improving timely detection of bladder and kidney cancer in primary care

Bladder and kidney cancer present with similar symptoms and are diagnosed via the same pathway. However, diagnosis of these cancers can be challenging, especially kidney cancer, where many of the symptoms are non-specific and around half of all patients are diagnosed incidentally when under investigation for an unrelated condition. Most of these two cancers are […]

read more

ASCO 2019: First-line pembrolizumab for advanced kidney cancer

Two presentations on the results of the KEYNOTE-427 clinical trial were given at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago this week. KEYNOTE-427 is an open-label, multicentre, global phase 2 study evaluating the efficacy and safety of pembrolizumab as a first-line treatment for patients with advanced or metastatic renal cell […]

read more

ASCO 2019: Treatment of sarcomatoid kidney cancer

The following presentation from the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago this week, summarises the findings regarding the treatment of sarcomatoid renal cell carcinoma (RCC) presented in three papers at the meeting. Around 10-20% of patients with advanced RCC are thought to have sarcomatoid histology. Tumours with sarcomatoid histology have […]

read more

ASCO 2019: Immunotherapy before surgery for treating metastatic kidney cancer

The results of this open-label pilot study were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago earlier this week. The study investigated the use of neoadjuvant (before surgery) immunotherapy in patients with metastatic renal cell carcinoma (RCC). One hundred and five patients with metastatic RCC were randomised to receive […]

read more
Showing 1 to 10 of 415 results
  TOP